Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25918657 | 0.82 | SLC40A1 (0.39) | PTGS1PTGS2KDM4EKMT2ABACE1 | |
| SCHEMBL25317922 | 0.73 | CYP4F2 (0.35) | PTGS2BACE1SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL2645976 | 0.71 | NFE2L2 (0.41) | PTK2PTGS1PTGS2POLBKDM4E | |
| SCHEMBL25316966 | 0.71 | CYP4F2 (0.32) | — | |
| SCHEMBL1465207 | 0.69 | NFE2L2 (0.42) | PTK2POLBKDM4EMEN1KMT2A | |
| SCHEMBL25316626 | 0.69 | SMYD3 (0.35) | POLBKDM4EGRM4NFE2L2 | |
| SCHEMBL30507020 | 0.69 | RAB9A (0.43) | PTK2MEN1KMT2AL3MBTL1NAMPT | |
| SCHEMBL25314065 | 0.69 | RAB9A (0.43) | PTK2MEN1KMT2AL3MBTL1NAMPT | |
| SCHEMBL30727325 | 0.68 | NFE2L2 (0.39) | PTK2PTGS1PTGS2POLBKDM4E | |
| SCHEMBL27326807 | 0.68 | NFE2L2 (0.39) | PTK2PTGS1PTGS2POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | PTK2 4034/4885PTGS1 2213/4885PTGS2 3430/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | PTK2 4156/4885PTGS1 2327/4885PTGS2 3437/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | PTK2 4034/4885PTGS1 2213/4885PTGS2 3430/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | PTK2 4156/4885PTGS1 2327/4885PTGS2 3437/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | PTK2 4156/4885PTGS1 2327/4885PTGS2 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.